BeOne Medicines Reports Positive Phase 3 Survival Data for Ziihera Regimens

MT Newswires Live08-31

BeOne Medicines (ONC) said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.

The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.

The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.

Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2663074010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663074010","market":"sh","top_or_hot":-1,"title":"BeOne Medicines Reports Positive Phase 3 Survival Data for Ziihera Regimens","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines (ONC) said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.</p><p>The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.</p><p>The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.</p><p>Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Reports Positive Phase 3 Survival Data for Ziihera Regimens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Reports Positive Phase 3 Survival Data for Ziihera Regimens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-31 18:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeOne Medicines (ONC) said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.</p><p>The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.</p><p>The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.</p><p>Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663074010","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663074010","pubTimestamp":1788172616,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines  said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ONC":"百济神州","MDCO":"麦迪逊医药"},"translate_title":"BeOne Medicines报告Ziihera方案的积极3期生存数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1,"MDCO":1.5},"content_text":"BeOne Medicines (ONC) said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663074010","isCrawlerRequest":true}